These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9437361)

  • 1. Cost of fosphenytoin.
    Fierro L; Hudak J
    Ann Emerg Med; 1998 Jan; 31(1):137-8; author reply 138-9. PubMed ID: 9437361
    [No Abstract]   [Full Text] [Related]  

  • 2. Fosphenytoin farewell?
    Horowitz BZ
    Ann Emerg Med; 2004 Mar; 43(3):398-400. PubMed ID: 14985669
    [No Abstract]   [Full Text] [Related]  

  • 3. Phenytoin and fosphenytoin: a model of cost and clinical outcomes.
    Armstrong EP; Sauer KA; Downey MJ
    Pharmacotherapy; 1999 Jul; 19(7):844-53. PubMed ID: 10417033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department.
    Rudis MI; Touchette DR; Swadron SP; Chiu AP; Orlinsky M
    Ann Emerg Med; 2004 Mar; 43(3):386-97. PubMed ID: 14985668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fosphenytoin: worth the cost?
    Miller MH
    Ann Emerg Med; 1997 Jun; 29(6):823. PubMed ID: 9174533
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost of fosphenytoin.
    Marble EL
    Ann Emerg Med; 1998 Jan; 31(1):138-9. PubMed ID: 9437362
    [No Abstract]   [Full Text] [Related]  

  • 7. Inappropriate fosphenytoin use in the ED.
    Johnson J; Wrenn K
    Am J Emerg Med; 2001 Jul; 19(4):293-4. PubMed ID: 11447516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic considerations in treatment options for acute seizures.
    Graves N
    J Child Neurol; 1998 Oct; 13 Suppl 1():S27-9; discussion S30-2. PubMed ID: 9796750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fosphenytoin. Pharmacoeconomic implications of therapy.
    Holliday SM; Benfield P; Plosker GL
    Pharmacoeconomics; 1998 Dec; 14(6):685-90. PubMed ID: 10346419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic evaluation of intravenous fosphenytoin (Cerebyx) versus intravenous phenytoin (Dilantin) in hospital emergency departments.
    Marchetti A; Magar R; Fischer J; Sloan E; Fischer P
    Clin Ther; 1996; 18(5):953-66. PubMed ID: 8930434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.
    DeToledo JC; Lowe MR; Rabinstein A; Villaviza N
    Epilepsia; 2001 Feb; 42(2):288. PubMed ID: 11240605
    [No Abstract]   [Full Text] [Related]  

  • 12. Reactions to fosphenytoin editorial and review article.
    Hopefl A
    Am J Health Syst Pharm; 1997 Feb; 54(4):445. PubMed ID: 9043574
    [No Abstract]   [Full Text] [Related]  

  • 13. Fosphenytoin: a novel phenytoin prodrug.
    Boucher BA
    Pharmacotherapy; 1996; 16(5):777-91. PubMed ID: 8888074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reactions to fosphenytoin editorial and review article.
    Paloucek FP
    Am J Health Syst Pharm; 1997 Feb; 54(4):449. PubMed ID: 9043575
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-minimization analysis of phenytoin and fosphenytoin in the emergency department.
    Touchette DR; Rhoney DH
    Pharmacotherapy; 2000 Aug; 20(8):908-16. PubMed ID: 10939551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactions to fosphenytoin editorial and review article.
    Orr J
    Am J Health Syst Pharm; 1997 Feb; 54(4):442, 445. PubMed ID: 9043573
    [No Abstract]   [Full Text] [Related]  

  • 17. Reactions to fosphenytoin editorial and review article.
    Matheson C
    Am J Health Syst Pharm; 1997 Feb; 54(4):441-2. PubMed ID: 9043571
    [No Abstract]   [Full Text] [Related]  

  • 18. Fosphenytoin safety and economics.
    Paloucek FP
    Am J Health Syst Pharm; 1996 Nov; 53(22):2702. PubMed ID: 8931811
    [No Abstract]   [Full Text] [Related]  

  • 19. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.
    DeToledo JC; Ramsay RE
    Drug Saf; 2000 Jun; 22(6):459-66. PubMed ID: 10877039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosphenytoin.
    Eriksson K; Keränen T; Kälviäinen R
    Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):695-701. PubMed ID: 19473113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.